您当前所在的位置:首页 > 产品中心 > 产品信息
Potassium Chloride_分子结构_CAS_7447-40-7)
点击图片或这里关闭

Potassium Chloride

产品号 DB00761 公司名称 DrugBank
CAS号 7447-40-7 公司网站 http://www.ualberta.ca/
分子式 ClK 电 话 (780) 492-3111
分子量 74.5513 传 真
纯 度 电子邮件 david.wishart@ualberta.ca
保 存 Chembase数据库ID: 641

产品价格信息

请登录

产品别名

标题
Potassium Chloride
IUPAC标准名
potassium chloride
IUPAC传统名
potassium ion chloride
商标名
Repone-K
KCl
K-SR
Potasol
Enpott
Micro-K LS
Cena-K
K-Lyte/Cl
K-Sol
Kalinor-Retard P
Kalinorm
Kalitrans Retard
Kalium Retard
Kalium-R
Keylyte
Klotrix
Steropotassium
Chlorvescent
Durules-K
Emplets potassium chloride
K-Care
K-Contin
K-Grad
K. tab
KSR
Kaliolite
Kaon Ultra
Kay-Ciel
Kayback
Kelp salt
Micro-K Extentcaps
Neobakasal
Peter-kal
Pfiklor
Potasion
Rekawan Retard
Rum-K
Sal digestnum sylvii
Slow-K
Apo-K
Celeka
Chloropotassuril
Chloropotassuril diffu-K
Colyte
Duffi-K
Durekal
Durules
Enseal
Infalyte
K-Lyte Cl
K-Tab
K-lyte/C1
KCL Retard
KCl-retard Zyma
KM potassium chloride
Kalcorid
Kaleorid
Kaliglutol
Kalilente
Kalipoz
Kalium Duriles
Kalium S.R.
Kalium-duriles
Kaon CL
Kaon-Cl
Kato
Kay-cee-l
Klor-Con M20
Klor-Lyte
Leo K
Leo-K
Micro-Kalium Retard
Miopotasio
Potassium Chloride BP
Potassium muriate
Potavescent
Rekawan
Span-K
Super K
Trona muriate of potash
Trona potassium chloride
Ultra K Chlor
Acronitol
Addi-K
Clor-K-Zaf
Diffu-K
K Tab
K-Lease
K-Lor
K-Norm
K-Predne-dome
K-dur
Kadalex
Kaleorod
Kaliduron
Kalipor
Kalitabs
Kalium Durules
Kalium SR
Kalium-Durettes
Kaliumchlorid
Kaochlor
Kaon-ci
Kaskay
Kay Ciel
Kay-EM
Klor-Con
Kloren
Klorvess
Kolyum
Lento-K
Lento-kalium
Micro-K
Muriate of potash
Natural sylvite
Nu-K
Plus Kalium Retard
Potassium Chloride 10meq in Plastic Container
Repone K
Sando-K
Selora
Ten-K
Ultra-K-Chlor
别名
Hydrochloric acid potassium salt (1:1)
Dipotassium dichloride
Tripotassium trichloride
Chloride of potash
Chlorid draselny [Czech]
ClK
Monopotassium chloride
Potassium thallium chloride (KTlCl)
Potassium monochloride

产品登记号

CAS号 7447-40-7
PubChem CID 4873
PubChem SID 46506038

产品性质

溶解度 Freely soluble

产品详细信息

详细说明 (English)
Item Information
Drug Groups approved; withdrawn
Description A white crystal or crystalline powder used as an electrolyte replenisher, in the treatment of hypokalemia, in buffer solutions, and in fertilizers and explosives.
Indication For use as an electrolyte replenisher and in the treatment of hypokalemia.
Pharmacology The potassium ion is in the principle intracellular cation of most body tissues. Potassium ions participate in a number of essential physiological processes including the maintenance of intracellular tonicity, the transmission of nerve impulses, the contraction of cardiac, skeletal and smooth muscle, and the maintenance of normal renal function. The intracellular concentration of potassium is approximately 150 to 160 mEq per liter. The normal adult plasma concentration is 3.5 to 5 mEq per liter. An active ion transport system maintains this gradient across the plasma membrane. Potassium is a normal dietary constituent and under steady-state conditions the amount of potassium absorbed from the gastrointestinal tract is equal to the amount excreted in the urine. The usual dietary intake of potassium is 50 to 100 mEq per day. Potassium depletion will occur whenever the rate of potassium loss through renal excretion and/or loss from the gastrointestinal tract exceeds the rate of potassium intake. Such depletion usually develops as a consequence of therapy with diuretics, primarily or secondary hyperaldosteronism, diabetic ketoacidosis, or inadequate replacement of potassium in patients on prolonged parenteral nutrition. Depletion can develop rapidly with severe diarrhea, especially if associated with vomiting. Potassium depletion due to these causes is usually accompanied by concomitant loss of chloride and is manifested by hypokalemia and metabolic alkalosis. Potassium depletion may produce weakness, fatigue, disturbances of cardiac rhythm (primarily ectopic beats), prominent U-waves in the electrocardiogram, and, in advanced cases, flaccid paralysis and/or impaired ability to concentrate urine. If potassium depletion associated with metabolic alkalosis cannot be managed by correcting the fundamental cause of the deficiency, e.g., where the patient requires long-term diuretic therapy, supplemental potassium in the form of high potassium food or potassium chloride may be able to restore normal potassium levels. In rare circumstances (e.g., patients with renal tubular acidosis) potassium depletion may be associated with metabolic acidosis and hyperchloremia. In such patients, potassium replacement should be accomplished with potassium salts other than the chloride, such as potassium bicarbonate, potassium citrate, potassium acetate, or potassium gluconate.
Toxicity The administration of oral potassium salts to persons with normal excretory mechanisms for potassium rarely causes serious hyperkalemia. However, if excretory mechanisms are impaired, of if potassium is administered too rapidly intravenously, potentially fatal hyperkalemia can result. It is important to recognize that hyperkalemia is usually asymptomatic and may be manifested only by an increased serum potassium concentration (6.5-8.0 mEq/L) and characteristic electrocardiographic changes (peaking of T-waves, loss of P-wave, depression of S-T segment, and prolongation of the QT interval). Late manifestations include muscle paralysis and cardiovascular collapse from cardiac arrest (9-12 mEq/L).
Affected Organisms
Humans and other mammals
Absorption Potassium is a normal dietary constituent and under steady-state conditions the amount of potassium absorbed from the gastrointestinal tract is equal to the amount excreted in the urine.
Elimination Potassium is a normal dietary constituent and, under steady-state conditions, the amount of potassium absorbed from the gastrointestinal tract is equal to the amount excreted in the urine. Potassium depletion will occur whenever the rate of potassium loss through renal excretion and/or loss from the gastrointestinal tract exceeds the rate of potassium intake.
External Links
Wikipedia
RxList
Drugs.com

参考文献